Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | BPTF | Q12830 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477142 | 1.00 | FUCA1 (0.55) | FUCA1SIGMAR1BPTFDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL2264027 | 0.98 | FUCA1 (0.53) | FUCA1SIGMAR1BPTFDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL3018917 | 0.98 | FUCA1 (0.53) | FUCA1SIGMAR1BPTFDRD2DRD3 | |
| SCHEMBL16344546 | 0.90 | HRH4 (0.49) | FUCA1BPTFS1PR1S1PR5 | |
| SCHEMBL928351 | 0.88 | SIGMAR1 (0.50) | FUCA1SIGMAR1DRD2DRD3GRIN2B | |
| SCHEMBL3784554 | 0.88 | SIGMAR1 (0.50) | FUCA1SIGMAR1DRD2DRD3GRIN2B | |
| SCHEMBL6217555 | 0.88 | ACHE (0.55) | SIGMAR1DRD2DRD3 | |
| SCHEMBL6640228 | 0.88 | ACHE (0.55) | SIGMAR1DRD2DRD3 | |
| SCHEMBL3777655 | 0.88 | SIGMAR1 (0.50) | FUCA1SIGMAR1DRD2DRD3GRIN2B | |
| SCHEMBL3781490 | 0.88 | ACHE (0.55) | SIGMAR1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4428136-B1 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-26 | — | — | EP | disclosed |
| EP-4646197-A2 | ORGANIC COMPOUNDS AS NLRP3 INHIBITORS | Kodiak Sciences Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| WO-2025224085-A1 | COMPOUNDS CAPABLE OF ACTING ON S1R AS WELL AS ON SEH AND USES THEREOF | UNIVERSITAT DE BARCELONA (ES) | 2025-10-30 | — | — | WO | disclosed |
| US-20250243186-A1 | PIPERIDINYL INDOLE DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF | HANSOH BIO LLC. | 2025-07-31 | — | — | US | disclosed |
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMAC, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| EP-4428136-A2 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2024-09-11 | — | — | EP | disclosed |
| CN-113038952-B | Improved synthetic methods for preparing fused heterocyclic compounds as orexin receptor modulators | 詹森药业有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-118510765-A | Piperidinyl indole derivatives, preparation method and medical application thereof | 翰森生物有限责任公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2024148029-A2 | ORGANIC COMPOUNDS AS NLRP3 INHIBITORS | KODIAK SCIENCES INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-12030887-B2 | Synthetic methods of making fused heterocyclic compounds as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-09 | — | — | US | disclosed |
| US-6809105-B2 | (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA | ABBOTT LABORATORIES | 2004-10-26 | — | — | US | disclosed |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2004-09-23 | — | — | US | disclosed |
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | US | disclosed |
| CN-1440410-A | Diazabicyclic central nervous system active agents | ABBOTT LAB (US) | 2003-09-03 | — | — | CN | disclosed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | disclosed |
| EP-0828741-B1 | SPIROCYCLIC AND BICYCLIC DIAZINYL AND CARBAZINYL OXAZOLIDINONES | UPJOHN CO (US) | 2001-08-29 | — | — | EP | disclosed |
| US-6107321-A | Diazabicyclooctane derivatives having selective 5-HT1Dalpha agonist activity | MERCK SHARP & DOHME LTD. (GB) | 2000-08-22 | — | — | US | disclosed |
| US-6090820-A | MICROBIOCIDES, BATERICIDES | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0828741-A1 | SPIROCYCLIC AND BICYCLIC DIAZINYL AND CARBAZINYL OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996035691-A1 | SPIROCYCLIC AND BICYCLIC DIAZINYL AND CARBAZINYL OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | KCNH1, KCNH2, CACNA1E | FUCA1 3643/4885SIGMAR1 1091/4885BPTF 4466/4885 |
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | FUCA1 796/4885SIGMAR1 4534/4885BPTF 80/4885 |
| US-12030887-B2 | Synthetic methods of making fused heterocyclic compounds as orexin receptor modulators | HCRTR2, HCRTR1, HTR3D | FUCA1 4792/4885SIGMAR1 166/4885BPTF 3435/4885 |
| US-20250243186-A1 | PIPERIDINYL INDOLE DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF | IDO1, IDO2, TPH1 | FUCA1 1588/4885SIGMAR1 2242/4885BPTF 3417/4885 |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | FUCA1 2124/4885SIGMAR1 306/4885BPTF 4658/4885 |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | FUCA1 2124/4885SIGMAR1 306/4885BPTF 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.